Real-World Evidence for Baricitinib in the Treatment of Rheumatoid Arthritis in Spain: A Systematic Literature Review.

ABSTRACT:

Introduction

Baricitinib is a Janus kinase inhibitor approved for the treatment of moderate-to-severe rheumatoid arthritis (RA) in adults who have responded inadequately, or are intolerant, to disease-modifying antirheumatic drugs (DMARDs). This systematic literature review was conducted to understand the use of baricitinib in RA in the real-world setting in Spain.

Methods

Embase and MEDLINE databases were systematically searched for publications (in English or Spanish) published between March 2017 and June 2023; Spanish data presented at national rheumatology congresses were also obtained, with a date limitation of 2021-2023.

Results

Nineteen eligible publications were identified (5 full papers, 14 conference abstracts), including more than 1000 patients who received

SUBMITTER: Rosas J 

PROVIDER: S-EPMC12006230 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature